Table 2.
Odds of having a chronic diseases at study entry in patients exposed and unexposed to periodontal diseases
| All cardiovascular disease | Heart failure | Ischaemic heart disease | Stroke/transient-ischaemic attack | Peripheral vascular disease | ||||||
| Exposed | Unexposed | Exposed | Unexposed | Exposed | Unexposed | Exposed | Unexposed | Exposed | Unexposed | |
| Total no of patients | 64 379 | 251 161 | 64 379 | 251 161 | 64 379 | 251 161 | 64 379 | 251 161 | 64 379 | 251 161 |
| No of patients with condition at baseline, n (%) | 6355 (9.87) | 18 594 (7.40) | 977 (1.52) | 2608 (1.04) | 3963 (6.16) | 11 759 (4.68) | 2161 (3.36) | 6154 (2.45) | 860 (1.34) | 2345 (0.93) |
| OR (95% CI)* | 1.37 (1.33 to 1.41) | 1.47 (1.36 to 1.58) | 1.34 (1.29 to 1.39) | 1.38 (1.32 to 1.45) | 1.44 (1.33 to 1.55) | |||||
| P value | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | |||||
| aOR (95% CI)† | 1.43 (1.38 to 1.48) | 1.43 (1.32 to 1.54) | 1.34 (1.28 to 1.39) | 1.36 (1.29 to 1.44) | 1.37 (1.26 to 1.49) | |||||
| P value | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | |||||
| Vascular dementia | All cardiometabolic disease | Type 2 diabetes mellitus | Hypertension | All autoimmune conditions | ||||||
| Exposed | Unexposed | Exposed | Unexposed | Exposed | Unexposed | Exposed | Unexposed | Exposed | Unexposed | |
| Total no of patients | 64 379 | 251 161 | 64 379 | 251 161 | 64 379 | 251 161 | 64 379 | 251 161 | 64 379 | 251 161 |
| No of patients with condition at baseline, n (%) | 146 (0.23) | 363 (0.14) | 12 321 (19.14) | 42 828 (17.05) | 3432 (5.33) | 10 342 (4.12) | 10 841 (16.84) | 38 649 (15.39) | 5265 (8.18) | 15 690 (6.25) |
| OR (95% CI)* | 1.57 (1.30 to 1.90) | 1.15 (1.13 to 1.18) | 1.31 (1.26 to 1.36) | 1.11 (1.09 to 1.14) | 1.34 (1.29 to 1.38) | |||||
| P value | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | |||||
| aOR (95% CI)† | 1.47 (1.20 to 1.79) | 1.16 (1.13 to 1.19) | 1.23 (1.18 to 1.28) | 1.11 (1.08 to 1.15) | 1.33 (1.28 to 1.37) | |||||
| P value | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | |||||
| Type 1 diabetes mellitus | Rheumatoid arthritis | Systemic lupus erythematosus | Sjogren | Vitiligo | ||||||
| Exposed | Unexposed | Exposed | Unexposed | Exposed | Unexposed | Exposed | Unexposed | Exposed | Unexposed | |
| Total no of patients | 64 379 | 251 161 | 64 379 | 251 161 | 64 379 | 251 161 | 64 379 | 251 161 | 64 379 | 251 161 |
| No of patients with condition at baseline, n (%) | 591 (0.92) | 1473 (0.59) | 656 (1.02) | 1786 (0.71) | 164 (0.25) | 346 (0.14) | 103 (0.16) | 189 (0.08) | 239 (0.37) | 629 (0.25) |
| OR (95% CI)* | 1.57 (1.43 to 1.73) | 1.44 (1.31 to 1.57) | 1.85 (1.54 to 2.23) | 2.13 (1.67 to 2.71) | 1.48 (1.28 to 1.72) | |||||
| P value | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | |||||
| aOR (95% CI)† | 1.55 (1.41 to 1.71) | 1.39 (1.27 to 1.53) | 1.79 (1.48 to 2.16) | 1.99 (1.56 to 2.54) | 1.40 (1.20 to 1.62) | |||||
| P value | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | |||||
| Psoriasis | Pernicious anaemia | Inflammatory bowel disease | Coeliac | Autoimmune thyroiditis | ||||||
| Exposed | Unexposed | Exposed | Unexposed | Exposed | Unexposed | Exposed | Unexposed | Exposed | Unexposed | |
| Total no of patients | 64 379 | 251 161 | 64 379 | 251 161 | 64 379 | 251 161 | 64 379 | 251 161 | 64 379 | 251 161 |
| No of patients with condition at baseline, n (%) | 2615 (4.06) | 8105 (3.23) | 231 (0.36) | 738 (0.29) | 560 (0.87) | 1767 (0.70) | 206 (0.32) | 576 (0.23) | 209 (0.32) | 721 (0.29) |
| OR (95% CI)* | 1.27 (1.21 to 1.33) | 1.22 (1.05 to 1.42) | 1.24 (1.13 to 1.36) | 1.40 (1.19 to 1.64) | 1.13 (0.97 to 1.32) | |||||
| P value | <0.01 | <0.01 | <0.01 | <0.01 | 0.12 | |||||
| aOR (95% CI)† | 1.27 (1.21 to 1.33) | 1.16 (1.00 to 1.35) | 1.24 (1.12 to 1.36) | 1.40 (1.19 to 1.65) | 1.12 (0.96 to 1.31) | |||||
| P value | <0.01 | 0.05 | <0.01 | <0.01 | 0.16 | |||||
| Scleroderma | All mental health conditions | Depression | Anxiety | Severe mental illness | ||||||
| Exposed | Unexposed | Exposed | Unexposed | Exposed | Unexposed | Exposed | Unexposed | Exposed | Unexposed | |
| Total no of patients | 64 379 | 251 161 | 64 379 | 251 161 | 64 379 | 251 161 | 64 379 | 251 161 | 64 379 | 251 161 |
| No of patients with condition at baseline, n (%) | 42 (0.07) | 94 (0.04) | 19 142 (29.73) | 48 998 (19.51) | 13 496 (20.96) | 34 415 (13.70) | 9623 (14.95) | 22 093 (8.80) | 1242 (1.93) | 2905 (1.16) |
| OR (95% CI)* | 1.74 (1.21 to 2.51) | 1.75 (1.71 to 1.78) | 1.67 (1.63 to 1.71) | 1.82 (1.78 to 1.87) | 1.68 (1.57 to 1.80) | |||||
| P value | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | |||||
| aOR (95% CI)† | 1.69 (1.17 to 2.44) | 1.79 (1.75 to 1.83) | 1.69 (1.65 to 1.73) | 1.83 (1.79 to 1.88) | 1.66 (1.55 to 1.77) | |||||
| P value | <0.01 | p<0.01 | <0.01 | <0.01 | <0.01 | |||||
*Unadjusted OR.
†AOR: adjusted for age, sex, body mass index, Townsend Deprivation Index, smoking status and ethnicity at baseline.
aOR, adjusted OR.